1. Home
  2. PRPL vs TVRD Comparison

PRPL vs TVRD Comparison

Compare PRPL & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Purple Innovation Inc.

PRPL

Purple Innovation Inc.

HOLD

Current Price

$8.94

Market Cap

34.1M

ML Signal

HOLD

Logo Tvardi Therapeutics Inc.

TVRD

Tvardi Therapeutics Inc.

HOLD

Current Price

$2.01

Market Cap

27.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRPL
TVRD
Founded
2010
2017
Country
United States
United States
Employees
N/A
12
Industry
Home Furnishings
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.1M
27.5M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
PRPL
TVRD
Price
$8.94
$2.01
Analyst Decision
Hold
Buy
Analyst Count
2
7
Target Price
$0.65
$29.50
AVG Volume (30 Days)
173.0K
6.5M
Earning Date
04-28-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
152.75
N/A
EPS
N/A
N/A
Revenue
$468,725,000.00
N/A
Revenue This Year
$8.50
N/A
Revenue Next Year
$6.68
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$1.50
52 Week High
$8.50
$43.65

Technical Indicators

Market Signals
Indicator
PRPL
TVRD
Relative Strength Index (RSI) 86.98 38.74
Support Level $0.54 $1.50
Resistance Level N/A $4.32
Average True Range (ATR) 0.62 0.30
MACD 0.40 -0.10
Stochastic Oscillator 98.58 4.14

Price Performance

Historical Comparison
PRPL
TVRD

About PRPL Purple Innovation Inc.

Purple Innovation Inc designs and manufactures sleep products. Using its GelFlex Grid technology, the company designs, manufactures, and offers branded comfort sleep products, including mattresses, pillows, cushions, mattress protectors, bases, sheets, and others. It markets and sells these products through direct-to-consumer e-commerce channels, retail brick-and-mortar wholesale partners, Purple showrooms, and third-party online retailers.

About TVRD Tvardi Therapeutics Inc.

Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.

Share on Social Networks: